The Denali Approach
Denali is investigating an innovative new approach 1,2,3
Denali has developed an investigational technology designed to broadly and efficiently deliver the Iduronate-2-sulfatase (IDS) enzyme across the blood-brain barrier to the neurons and other important cell types in the brain. This technology, Enzyme Transport Vehicle (ETV), is believed to specifically allow delivery of large-molecule therapeutics to the brain. DNL310, the investigational intravenous (IV) enzyme replacement therapy, aims to address the behavioral and cognitive aspects of Hunter syndrome while also maintaining benefit for the entire body.
Image is for descriptive purposes only. DNL310 is an investigational drug and is not approved by any Health Authority
Learn More About Clinical Trials
Whether you’re interested in active participation or just want to know about research in progress, see our latest clinical trial information here